Real-life anticoagulants benefit-risk in atrial fibrillation (AF) in France: VKA benefit-risk assessment before DOAC use for AF (ENGEL 1 VKA)First published 23/05/2014 Last updated 22/11/2022 EU PAS number: EUPAS6616StudyFinalisedDownload as PDF
Bordeaux PharmacoEpi, University of BordeauxFrance First published: 07/02/2023Last updated 08/02/2023 InstitutionEducational InstitutionHospital/Clinic/Other health care facilityNot-for-profitENCePP partner